Data from the phase 3 study confirmed the lot consistency, immunogenicity, safety, and tolerability of a toxoid-based Clostridioides difficile vaccine. Neutralizing antibody responses 1 month after ...
In a major step toward a precision therapy for Clostridioides difficile (C. diff) infection, researchers at The Hospital for Sick Children (SickKids) have uncovered how the body's bile acids bind to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results